FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Amazon Explores AI Content Marketplace With Media Publishers 
CHARLESTON, S.C., April 09, 2018 -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) is pleased to announce that it has filed its Management Information Circular for the upcoming Annual and Special Meeting of Shareholders. The Meeting will be held at the offices of Stikeman Elliott LLP, located on the 41st floor at 1155 René-Lévesque Blvd. West, Montreal, Quebec, Canada, H3B 3V2 on Tuesday, May 8, 2018, at 10:00 a.m. (Eastern Time). Shareholders will receive the audited consolidated financial statements of the Corporation for the year ended December 31, 2017, together with the auditors’ report thereon and be asked to elect directors; to appoint auditors and to authorize the directors to determine their compensation; and to consider the ordinary resolution to approve the long-term incentive plan of the Corporation. The Management Information Circular is available on www.sedar.com, www.sec.gov and on the Company website www.aezsinc.com.
The Company encourages shareholders to read the Management Information Circular in detail. Shareholders who have questions or have not received their proxy or voting instruction form may contact Aeterna Zentaris’ Proxy Solicitation Agent:
| Laurel Hill Advisory Group | |||
| Toll free: 1-877-452-7184 or 416-304-0211 | |||
| Email: [email protected] |
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency. Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.aezsinc.com.
Contacts:
Aeterna Zentaris Inc.
James Clavijo
Chief Financial Officer
[email protected]
843-900-3201
